Does mechanism of action always translate into efficacy?
What are the implications for your psoriasis patient's outcomes? A panel discussion with case study review. Understand the pathogenesis of plaque psoriasis, learn the development of targeted therapies for psoriasis, specifically IL-17A and IL-17F inhibitors, and understand the differences between the mechanism of action of biologic therapies. Particularly why the mechanism of action should be considered before prescribing a treatment for plaque psoriasis.
Presented by Dr Fiona Craig, Professor Brian Kirby, Dr Keith Wu and Dr Laura Savage.
Includes your reflective learning guide to download to obtain CPD accreditation.
Watch the full video to obtain CPD accreditation or watch in bite-size chunks by using the navigation below:
Does mode of action always translate into efficacy?
Case study 1
Case study 2
Report adverse events
Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk and hpra.ie/homepage/about-us/report-an-issue.
Adverse events should also be reported to UCB Pharma Ltd Email: UCBCares.UK@ucb.com and UCBCares.IE@ucb.com.
Help us to grow our resource the way you want it to grow.